PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $69.86M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 1.19M
Average 0.38M
Returns on capital
PMV Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-74.2%
avg -15.3%
ROIC
-79.5%
avg -33.3%
ROA
-66.7%
avg -28.9%
Analysis
ROA is currently the strongest return metric at -66.7% versus its period average of -28.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David H. Mack | Co-Founder, Chief Executive Officer, President & Director | USD 912.87K | 64 | — | — |
Deepika Jalota | Chief Development Officer | USD 653.07K | 49 | 303.31K | 0.57% |
Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary | USD 612K | 64 | 319.27K | 0.60% |
Michael Carulli | CFO & Principal Financial & Accounting Officer | USD 532.8K | 52 | 240.00K | 0.45% |
Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board | USD 140K | 86 | 42.00K | 0.08% |
Binh Vu | Senior Vice President of Drug Discovery & CMC | — | — | — | — |
Marc Fellous | Senior Vice President and Head of Clinical Development & Medical Affairs | — | — | — | — |
Philip Herman | Chief Commercial Officer | — | 47 | — | — |
Steve Dyott | Vice President of Marketing | — | — | — | — |
Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations | — | — | — | — |
Crystal Zuckerman | Vice President of Human Resources | — | — | — | — |
Laura De Leon | VP & Head of Clinical Development Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does PMV Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PMVP's management, answered from reported figures.
Who manages PMVP?
PMV Pharmaceuticals, Inc. (PMVP) lists 12 active executives. The top listed executive is Arnold J. Levine, Co-Founder, Independent Director & Member of Scientific Advisory Board.
Are PMVP insiders buying or selling?
Recent insider activity shows net selling of $24.22M.
Continue the stock analysis
Jump to another research area for this company.